Cooperative Induction of a Tolerogenic Dendritic Cell Phenotype by Cytokines Secreted by Pancreatic Carcinoma Cells-Reference-Cited by-同舟云学术

Cooperative Induction of a Tolerogenic Dendritic Cell Phenotype by Cytokines Secreted by Pancreatic Carcinoma Cells

Published:2006-08-18 Issue:5 Volume:177 Page:3448-3460
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Bellone Graziella,Carbone Anna,Smirne Carlo,Scirelli Tiziana,Buffolino Alessandra,Novarino Anna,Stacchini Alessandra,Bertetto Oscar,Palestro Giorgio,Sorio Claudio,Scarpa Aldo,Emanuelli Giorgio,Rodeck Ulrich

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference53 articles.

1. The use of dendritic cells in cancer immunotherapy

2. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival

3. Tumor-Associated Transforming Growth Factor-β and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients

4. Cancer vaccines: between the idea and the reality

5. The cell biology of antigen presentation in dendritic cells

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives;International Journal of Molecular Sciences;2024-09-03

2. TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function;Cell Reports Medicine;2024-08

3. Emerging Nanotechnology in Preclinical Pancreatic Cancer Immunotherapy: Driving Towards Clinical Applications;International Journal of Nanomedicine;2024-07

4. Current and future immunotherapeutic approaches in pancreatic cancer treatment;Journal of Hematology & Oncology;2024-06-04

5. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study;The Lancet Oncology;2024-04